Non-inflammatory Degenerative Joint DiseaseJourney UNINCT03442231
Journey™ UNI Post Market Clinical Follow-Up
An observational study of Non-inflammatory Degenerative Joint Disease, run by Smith & Nephew, Inc. at 4 sites in 2 countries.
Trial summary
This is a retrospective/prospective, open-label single cohort, multicenter study to collect relevant clinical data from subjects with unicompartmental degeneration of the knee in whom the Journey UNI UKS was previously implanted. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-inflammatory Degenerative Joint Disease
- What is being tested?
- Journey UNI Unicompartmental Knee System
- Type of treatment
- Medical device
- How many people
- 131 participants
- Where
- 4 sitesin 2 countries
- Study dates
- 11 Apr 2018to 25 Jan 2024
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Investigators will pre-screen all subjects that have previously undergone UKA using the Journey UNI UKS system between 12 and 48 months previously using only the existing information in the medical records.
Who may be able to join
- Between 12 and 48 months previously, subject had unicompartmental knee replacement implanted for unicompartmental, NIDJD including OA, traumatic arthritis, avascular necrosis, for correction of functional deformity, or to repair a fracture that was unmanageable using other techniques.
- Subject received a JOURNEY UNI UKS implant (consisting of a femoral component, tibial baseplate, and a tibial insert).
- Subject was considered skeletally mature at the time of surgery and was at least 18 years of age.
- Subject is willing to have retrospective data collected and to participate in required prospective follow-up visit(s) at the investigational site and to complete study procedures and questionnaires.
- Subject has consented to participate in the study by signing the Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form (ICF).
Who cannot join
- Subject has Body Mass Index (BMI) > 40 within 1 month of surgery.
- Subjects who have received the Journey UNI UKS as part of a revision surgery.
- Subject has a condition that may interfere with the unicompartmental knee arthroplasty (UKA) survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
- Subject has a known allergy to study device or one or more of its components.
- Subject, in the opinion of the Principal Investigator (PI), has an emotional or neurological condition that would preempt his/her ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
- Subject is entered in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days.
- Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.
Trial locations and contacts
4 sites in 2 countries.
4 sites in 2 countries
United States3 sites
Tennessee Orthopedic Alliance, P.A.
Nashville, Tennessee, 37209
Illinois Bone and Joint Institute
Park Ridge, Illinois, 60068
Orthopaedic Specialists of Central Arizona-Scottsdale
Scottsdale, Arizona, 85255
Canada1 site
London Health Sciences Centre-University Hospital
London, Ontario, N6A5A5
About this study
Official title: Follow-Up of Subjects With a Journey™ UNI Unicompartmental Knee System Implant
This is a retrospective/prospective, open-label single cohort, multicenter study to collect relevant clinical data from subjects with unicompartmental degeneration of the knee in whom the Journey UNI UKS was previously implanted.
Read the detailed description
The purpose of the current investigation is to assess the safety and effectiveness of the JOURNEY UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory degenerative joint disease (NIDJD) of the knee who previously had the Journey UNI UKS implanted. This clinical study will prospectively evaluate the 36 and 60-month safety and performance of the JOURNEY UNI UKS in patients with NIDJD of the knee who required lateral or medial knee compartment replacement.
- Being tested
- Journey UNI Unicompartmental Knee System
- Keywords
- osteoarthritis, traumatic arthritis, avascular necrosis
- Medical subject headings
- Osteoarthritis, Osteonecrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Journey UNI Unicompartmental Knee SystemDevice
Lateral or medial knee compartment replacement
| Study group | Role | What they receive |
|---|---|---|
| Journey™ UNI Unicompartmental Knee System | Subjects previously received knee replacement Receives: Device: Journey UNI Unicompartmental Knee System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant Survival
Revision-free implant survival at 5 years was determined by the proportion of participant knees with device survival. Revision-free implant survival was measured by a Kaplan-Meier survival estimate with survival defined as the absence of implant failure by the 5-year time point.
Measured: 5 years
Secondary outcomes (21)
2011 Knee Society Score (KSS): Objective Knee Score
The 2011 Knee Society Score consists of 4 separate sub-scales. The "Objective" Knee Score is seven items with a range of 0 to 111, with a higher score indicating a better outcome.
Measured: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Expectation Score
The 2011 Knee Society Score consists of 4 separate sub-scales. The Patient Expectation Score was three items with a range of 3 to 15 where higher scores indicated a better outcome. The Expectation score indicated the patient's opinion on the extent they expect the operation to improve their knee pain, and ability to perform activities of daily living and recreational activities.
Measured: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Satisfaction Knee Score
The 2011 Knee Society Score consists of 4 separate sub-scales. The Patient Satisfaction Score is five items with a range of 0 to 40, with a higher score indicating a better outcome.
Measured: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Functional Score
The 2011 Knee Society Score consists of 4 separate sub-scales. The Functional Score is nineteen items with a range of 0 to 100, with a higher score indicating a better outcome. Functional Score is derived from assessments of walking and standing, standard activities, advanced activities, and discretionary activities.
Measured: Baseline, 1 year, 3 years, 5 years
Five-level EuroQol Five-dimensional (EQ-5D-5L): Index Score
The EQ-5D-5L score consists of two parts: a descriptive system and a visual analogue scale (VAS). The Quality of Life index (i.e., index score) is used to describe the participant's health state and consists of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels to choose the most appropriate answer: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate their health state by marking the most appropriate statement in each of the five areas. The EQ-5D-5L Index Score was based on a US country code scale of -0.573 to 1, with higher index values indicating better health and lower index values indicating worse health.
Measured: 1 year, 3 years, 5 years
Five-level EuroQol Five-dimensional (EQ-5D-5L): Visual Analogue Scale (VAS) Score
The EQ-5D-5L score consists of two parts: a descriptive system and a visual analogue scale (VAS). The VAS records the participant's self-rated health on a vertical visual analogue scale. The scale ranges from 0 to 100 where 0 indicates 'The worst health you can imagine' and 100 indicates 'The best health you can imagine'.
Measured: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Surgery
Self-Administered Patient Satisfaction Survey indicated the participants satisfaction with outcomes of joint replacement surgery across four domains of pain relief, home/yard work, recreational activities, and overall satisfaction by a response to a single question for each domain. Participants were categorized based on the question "How satisfied are you with the results of your surgery?" for the associated knee using one of the following responses:
- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied
Measured: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Pain
Self-Administered Patient Satisfaction Survey indicated the participants satisfaction with outcomes of joint replacement surgery across four domains of pain relief, home/yard work, recreational activities, and overall satisfaction by a response to a single question for each domain. Participants were categorized based on the question "How satisfied are you with the results of your surgery for improving your pain?" for the associated knee using one of the following responses:
- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied
Measured: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Work
Self-Administered Patient Satisfaction Survey indicated the participants satisfaction with outcomes of joint replacement surgery across four domains of pain relief, home/yard work, recreational activities, and overall satisfaction by a response to a single question for each domain. Participants were categorized based on the question "How satisfied are you with the results of surgery for improving your ability to do home or yard work?" for the associated knee using one of the following responses:
- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied
Measured: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Recreational Activities
Self-Administered Patient Satisfaction Survey indicated the participants satisfaction with outcomes of joint replacement surgery across four domains of pain relief, home/yard work, recreational activities, and overall satisfaction by a response to a single question for each domain. Participants were categorized based on the question "How satisfied are you with the results of surgery for improving your ability to do recreational activities?" for the associated knee using one of the following responses:
- Very satisfied
- Somewhat satisfied
- Somewhat dissatisfied
- Very dissatisfied
Measured: 1 year, 3 years, 5 years
Forgotten Joint Score (FJS)
The Forgotten Joint Score (FJS) comprises measures for the assessment of joint-specific patient reported outcomes. Participants are asked to rate their awareness of their knee arthroplasty in 12 questions with a five point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". The item scores are summed and linearly transformed in a 0 to 100 scale with a high value reflecting the ability of the subject to forget about the replaced knee joint during the activities of daily living (i.e., a higher score is a better outcome).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Mechanical Alignment
Perform weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine the mechanical alignment in degrees.
Measured: Baseline, 6 months
Radiographic Findings: Implant Loosening
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine loosening of the implant (Yes/No).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Implant Subsidence/Migration
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine subsidence/migration of the implant (Yes/No).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Stress Shielding
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine presence of stress shielding (Yes/No).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Periprosthetic Fracture
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine periprosthetic fracture (Yes/No).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Wear of Articulating Surfaces of Replacement Components
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine wear of the articulating surfaces of replacement components (Yes/No).
Measured: 1 year, 3 years, 5 years
Radiographic Findings: Radiolucencies
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine if presence of radioloucencies were all negative (Yes/No). A 'Yes' response indicated no presence of radiolucent lines.
Measured: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Femoral Zone Radiolucencies
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine if presence of femoral zone radioloucencies were all negative (Yes/No). A 'Yes' response indicated no presence of radiolucent lines in the femoral zone of the knee.
Measured: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Anterior Medial-Lateral (ML) Zone Radiolucencies
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine if presence of anterior medial-lateral (ML) zone radioloucencies were all negative (Yes/No). A 'Yes' response indicated no presence of radiolucent lines in the anterior medial-lateral zone of the knee.
Measured: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Lateral Medial-Lateral (ML) Zone Radiolucencies
Performed weight-bearing antero-posterior (A/P) and lateral standard x-rays to determine if presence of lateral medial-lateral (ML) zone radioloucencies were all negative (Yes/No). A 'Yes' response indicated no presence of radiolucent lines in the lateral medial-lateral zone of the knee.
Measured: 6 months, 1 year, 3 years, 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2018
- Study start11 Apr 2018
- Primary completion25 Jan 2024
- Study completion25 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Non-inflammatory Degenerative Joint DiseaseStudies of the same condition, open and under way.
- More trials run by Smith & Nephew, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 131 participants (actual)
Sponsor and investigators
- Lead sponsor
- Smith & Nephew, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Patricia McCracken, Study chair, Smith & Nephew, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03442231
- Sponsor's protocol ID
- 17-4049-03
- Acronym
- Journey UNI
- Status last verified
- Feb 2024
- First submitted
- 16 Feb 2018
- Last updated
- 2 Nov 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Follow-Up of Subjects With a Journey™ UNI Unicompartmental Knee System Implant
- ClinicalTrials.gov ID
- NCT03442231
- Acronym / sponsor ID
- Journey UNI / 17-4049-03
- Keywords
- osteoarthritis, traumatic arthritis, avascular necrosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 131 participants (actual)
- Lead sponsor
- Smith & Nephew, Inc.Industry (pharma, biotech, devices)
- Study start
- 11 Apr 2018 (actual)
- Primary completion
- 25 Jan 2024 (actual)
- Study completion
- 25 Jan 2024 (actual)
- First posted
- 22 Feb 2018 (actual)
- Results
- Posted 2 Nov 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective/prospective, open-label single cohort, multicenter study to collect relevant clinical data from subjects with unicompartmental degeneration of the knee in whom the Journey UNI UKS was previously implanted.
Detailed description
The purpose of the current investigation is to assess the safety and effectiveness of the JOURNEY UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory degenerative joint disease (NIDJD) of the knee who previously had the Journey UNI UKS implanted. This clinical study will prospectively evaluate the 36 and 60-month safety and performance of the JOURNEY UNI UKS in patients with NIDJD of the knee who required lateral or medial knee compartment replacement.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Journey™ UNI Unicompartmental Knee System | – | Device: Journey UNI Unicompartmental Knee SystemSubjects previously received knee replacement |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Investigators will pre-screen all subjects that have previously undergone UKA using the Journey UNI UKS system between 12 and 48 months previously using only the existing information in the medical records.
Key inclusion criteria (5 listed)
- Between 12 and 48 months previously, subject had unicompartmental knee replacement implanted for unicompartmental, NIDJD including OA, traumatic arthritis, avascular necrosis, for correction of functional deformity, or to repair a fracture that was unmanageable using other techniques.
- Subject received a JOURNEY UNI UKS implant (consisting of a femoral component, tibial baseplate, and a tibial insert).
- Subject was considered skeletally mature at the time of surgery and was at least 18 years of age.
- Subject is willing to have retrospective data collected and to participate in required prospective follow-up visit(s) at the investigational site and to complete study procedures and questionnaires.
- Subject has consented to participate in the study by signing the Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form (ICF).
Key exclusion criteria (7 listed)
- Subject has Body Mass Index (BMI) > 40 within 1 month of surgery.
- Subjects who have received the Journey UNI UKS as part of a revision surgery.
- Subject has a condition that may interfere with the unicompartmental knee arthroplasty (UKA) survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
- Subject has a known allergy to study device or one or more of its components.
- Subject, in the opinion of the Principal Investigator (PI), has an emotional or neurological condition that would preempt his/her ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Journey UNI Unicompartmental Knee SystemLateral or medial knee compartment replacement | Device | Journey™ UNI Unicompartmental Knee System |
Primary outcome
Implant Survival
Time frame: 5 years
Revision-free implant survival at 5 years was determined by the proportion of participant knees with device survival. Revision-free implant survival was measured by a Kaplan-Meier survival estimate with survival defined as the absence of implant failure by the 5-year time point.
21 secondary outcomes
2011 Knee Society Score (KSS): Objective Knee Score
Time frame: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Expectation Score
Time frame: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Satisfaction Knee Score
Time frame: Baseline, 1 year, 3 years, 5 years
2011 Knee Society Score (KSS): Functional Score
Time frame: Baseline, 1 year, 3 years, 5 years
Five-level EuroQol Five-dimensional (EQ-5D-5L): Index Score
Time frame: 1 year, 3 years, 5 years
Five-level EuroQol Five-dimensional (EQ-5D-5L): Visual Analogue Scale (VAS) Score
Time frame: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Surgery
Time frame: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Pain
Time frame: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Work
Time frame: 1 year, 3 years, 5 years
Self-Administered Patient Satisfaction Survey (SAPSS): Recreational Activities
Time frame: 1 year, 3 years, 5 years
Forgotten Joint Score (FJS)
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Mechanical Alignment
Time frame: Baseline, 6 months
Radiographic Findings: Implant Loosening
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Implant Subsidence/Migration
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Stress Shielding
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Periprosthetic Fracture
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Wear of Articulating Surfaces of Replacement Components
Time frame: 1 year, 3 years, 5 years
Radiographic Findings: Radiolucencies
Time frame: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Femoral Zone Radiolucencies
Time frame: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Anterior Medial-Lateral (ML) Zone Radiolucencies
Time frame: 6 months, 1 year, 3 years, 5 years
Radiographic Findings: Lateral Medial-Lateral (ML) Zone Radiolucencies
Time frame: 6 months, 1 year, 3 years, 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Non-inflammatory Degenerative Joint Disease
RecruitingObservational study
Tornier Perform™ Reversed Monopost Study
Non-inflammatory Degenerative Joint Disease, Rhematoid Arthritis
Active, not recruitingObservational study
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
Rheumatoid Arthritis With Adequate Bone Quality, Inflammatory Arthritis
RecruitingObservational study
"Translating Articular Biomarkers Into Diagnoses"
Inflammatory and Non-inflammatory Bone and Joint Diseases
Active, not recruitingObservational study
Comprehensive Segmental Revision System
Degenerative Disease, Oncology
Active, not recruiting
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
Hip Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricia McCracken study chair
Smith & Nephew, Inc.
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-inflammatory Degenerative Joint Disease, run by Smith & Nephew, Inc. at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Nov 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implant Survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.